[Ip-health] Cost 'set to rule out successful hepatitis C drug'

Mohga Kamal-Yanni mkamalyanni at Oxfam.org.uk
Sun Oct 5 06:08:26 PDT 2014

>From the UK Independent newspaper

Comment on the story in the Independent
Why is the price so high? "A study by researchers at Liverpool University 
looked at the total real cost of the active pharmaceutical ingredients and 
the cost of manufacturing of the new direct anti-viral medicines class, of 
which sofosbuvir is one. They estimated the cost of a 12-week course of 
treatment with the combination of sofosbuvir and daclatasvir as US $78 per 

Yet the blame goes to NHS or NICE or anybody except the real culprit: the 
intellectual property system that guarantees monopoly of pharmaceutical 
companies and thus their ability to charge the price that can maximise 
their profit.

France and US are making the same complaints about the price of this 

At last rich countries woke up to the un-sustainability of the high priced 
medicines. Hepatitis C medicine is not a specific case. Recently, NICE 
rejected a cancer medicine made by Roche because of its high price.

It is high time, the world changes the system that governs research and 
development (R&D) and hence prices and get out of the prison of 
intellectual property. 

Best wishes 
Mohga (Dictating to the computer so please forgive silly mistakes) also 
have computer problems so please forgive delays
Mohga M Kamal-Yanni
Senior health & HIV policy advisor, Oxfam GB
John Smith Drive, Oxford, OX4 2JY, UK
UK Mobile   + 44 (0)777 62 55 884
Follow me @MohgaKamalYanni

Oxfam works with others to overcome poverty and suffering.

Oxfam GB is a member of Oxfam International and a company limited by guarantee registered in England No. 612172.
Registered office: Oxfam House, John Smith Drive, Cowley, Oxford, OX4 2JY.
A registered charity in England and Wales (no 202918) and Scotland (SC 039042)

More information about the Ip-health mailing list